Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hypersensitivity Reaction

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 192 articles: HTML format

Single Articles

July 2024
1. WILKINSON A, Woodcock A
   High-quality and low-carbon asthma care go hand in hand.
   Eur Respir J. 2024;64:2400638.
   PubMed    
   
   
   
2. SOUMAGNE T, Degano B
   Real world evidence in asthma: what to expect beyond randomised controlled trials?
   Eur Respir J. 2024;64:2400716.
   PubMed    
   
   
   June 2024
3. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
   IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
   Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
   PubMed    
   
   
   
4. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
   Clinical remission with biologic therapies in severe asthma: a matter of definition.
   Eur Respir J. 2024;63:2400160.
   PubMed     Abstract available
   
   
   
5. BEASLEY R, Noble J, Weatherall M
   The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
   Eur Respir J. 2024;63:2400523.
   PubMed     Abstract available
   
   
   
6. SUOJALEHTO H, Charles-Poucel S, Suuronen K, Ronsmans S, et al
   Presenting clinical data for the hazard classification of chemical respiratory sensitisers.
   Eur Respir J. 2024;63:2400338.
   PubMed    
   
   
   May 2024
7. MOSS RB
   T-cells and precision medicine for allergic bronchopulmonary aspergillosis.
   Eur Respir J. 2024;63:2400549.
   PubMed    
   
   
   
8. RAMAKRISHNAN S, Montgomery B, Pavord ID
   Blood eosinophils and lung function loss: from passive prediction to active prevention?
   Eur Respir J. 2024;63:2400812.
   PubMed    
   
   
   
9. BUSH A, Randerath W, Roche N
   As needed ICS/formoterol: not all of Europe is equal.
   Eur Respir J. 2024;63:2400408.
   PubMed    
   
   
   
10. HONG YS, Park HY, Ryu S, Shin SH, et al
    The association of blood eosinophil counts and FEV(1) decline: a cohort study.
    Eur Respir J. 2024;63:2301037.
    PubMed     Abstract available
    
    
    
11. POLVERINO F, Sin DD
    Type 2 airway inflammation in COPD.
    Eur Respir J. 2024;63:2400150.
    PubMed     Abstract available
    
    
    April 2024
12. HATTER L, Holliday M, Eathorne A, Bruce P, et al
    The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
    Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
    PubMed     Abstract available
    
    
    
13. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
    Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
    Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
    PubMed     Abstract available
    
    
    
14. KRISHNAN JA, Buhl R
    As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2302308.
    PubMed    
    
    
    
15. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
    Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2400395.
    PubMed    
    
    
    
16. 
    ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:24E6304.
    PubMed    
    
    
    
17. BLOOM CI
    Reply: Asthma and cardiovascular disease: the strength of triangulation.
    Eur Respir J. 2024;63:2400554.
    PubMed    
    
    
    
18. TATTERSALL MC, Gangnon RE, Jarjour NN
    Asthma and cardiovascular disease: embracing disease heterogeneity is required.
    Eur Respir J. 2024;63:2400469.
    PubMed    
    
    
    
19. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
    Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
    Eur Respir J. 2024;63:2301568.
    PubMed     Abstract available
    
    
    
20. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    PubMed     Abstract available
    
    
    March 2024
21. LUO RG, Wu YF, Lu HW, Weng D, et al
    Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
    PubMed     Abstract available
    
    
    
22. LIU T, Liu S, Rui X, Cao Y, et al
    Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
    Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
    PubMed     Abstract available
    
    
    
23. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
    The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
    Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
    PubMed     Abstract available
    
    
    February 2024
24. AGARWAL R, Singh Sehgal I, Muthu V, Denning DW, et al
    Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA working group.
    Eur Respir J. 2024 Feb 29:2400061. doi: 10.1183/13993003.00061-2024.
    PubMed     Abstract available
    
    
    
25. STANOJEVIC S, Kaminsky DA, Miller MR, Thompson B, et al
    Reply to: ERS/ATS spirometry interpretation standards: a gap in grading severity of airflow obstruction.
    Eur Respir J. 2024;63:2400055.
    PubMed    
    
    
    
26. WANG T, Duan W, Jia X, Huang X, et al
    Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
    Eur Respir J. 2024;63:2301720.
    PubMed     Abstract available
    
    
    January 2024
27. ZHU Z
    Early-life airway microbiome and childhood asthma development.
    Eur Respir J. 2024;63:2302187.
    PubMed    
    
    
    
28. DHOORIA S, Sehgal IS, Agarwal R
    Reply: A suggested classification of disease behaviour and treatment response in sarcoidosis trials.
    Eur Respir J. 2024;63:2302208.
    PubMed    
    
    
    
29. JENY F, Nunes H, Valeyre D
    In sarcoidosis trials, time also matters.
    Eur Respir J. 2024;63:2301629.
    PubMed    
    
    
    
30. HOGMAN M, Bowerman C, Chavez L, Dressel H, et al
    ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (F (ENO(50)) ).
    Eur Respir J. 2024;63:2300370.
    PubMed     Abstract available
    
    
    
31. 
    ERJ Podcast January 2024: The microbiome in early life and childhood asthma.
    Eur Respir J. 2024;63:24E6301.
    PubMed    
    
    
    December 2023
32. SUNDE RB MD PHD, Thorsen J MD PhD, Kim M MSc PhD, Schoos AM MD PhD, et al
    Bacterial Colonization of the Airway in Neonates and Risk of Asthma and Allergy Until Age 18 Years.
    Eur Respir J. 2023 Dec 14:2300471. doi: 10.1183/13993003.00471-2023.
    PubMed     Abstract available
    
    
    
33. BEASLEY R, Noble J, Weatherall M
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2023;62:2301844.
    PubMed    
    
    
    
34. WECKMANN M, Reddy KD
    Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow.
    Eur Respir J. 2023;62:2301552.
    PubMed    
    
    
    November 2023
35. VALENCIA-HERNANDEZ CA, Del Greco M F, Sundaram V, Portas L, et al
    Asthma and incident coronary heart disease: an observational and Mendelian randomisation study.
    Eur Respir J. 2023 Nov 9:2301788. doi: 10.1183/13993003.01788-2023.
    PubMed     Abstract available
    
    
    
36. CIVIDINI S, Sinha I, Donegan S, Maden M, et al
    Best step-up treatments for children with uncontrolled asthma: A systematic review and network meta-analysis of individual participant data.
    Eur Respir J. 2023 Nov 9:2301011. doi: 10.1183/13993003.01011-2023.
    PubMed     Abstract available
    
    
    
37. MORGAN C, Higbee D
    An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease.
    Eur Respir J. 2023;62:2302009.
    PubMed    
    
    
    October 2023
38. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission in severe asthma with Biologic Therapy: an analysis from the UK Severe Asthma Registry.
    Eur Respir J. 2023 Oct 19:2300819. doi: 10.1183/13993003.00819-2023.
    PubMed     Abstract available
    
    
    
39. HERRERA-LUIS E, de la Rosa-Baez C, Huntsman S, Eng C, et al
    Novel insights into the whole blood DNA methylome of asthma in ethnically diverse children and youth.
    Eur Respir J. 2023 Oct 6:2300714. doi: 10.1183/13993003.00714-2023.
    PubMed     Abstract available
    
    
    
40. 
    October Podcast: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma.
    Eur Respir J. 2023;62:23E6204.
    PubMed    
    
    
    September 2023
41. FIOCCHI AG, Phipatanakul W, Zeiger RS, Durrani SR, et al
    Dupilumab leads to better-controlled asthma & quality of life in children: the VOYAGE study.
    Eur Respir J. 2023 Sep 21:2300558. doi: 10.1183/13993003.00558-2023.
    PubMed     Abstract available
    
    
    
42. PAPI A, Ferreira DS, Agache I, Baraldi E, et al
    European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma.
    Eur Respir J. 2023 Sep 7:2300047. doi: 10.1183/13993003.00047-2023.
    PubMed     Abstract available
    
    
    
43. DHOORIA S, Sehgal IS, Agarwal R, Muthu V, et al
    High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial).
    Eur Respir J. 2023;62:2300198.
    PubMed     Abstract available
    
    
    August 2023
44. VON BULOW A, Hansen S, Sandin P, Ernstsson O, et al
    Severe asthma trajectories in adults: findings from the NORDSTAR cohort.
    Eur Respir J. 2023 Aug 24:2202474. doi: 10.1183/13993003.02474-2022.
    PubMed     Abstract available
    
    
    
45. POWELL WT, Reeves SR
    From small to big, using microRNA profiling to investigate infant origins of childhood asthma.
    Eur Respir J. 2023;62:2301052.
    PubMed    
    
    
    
46. OSADNIK CR, Brighton LJ, Burtin C, Cesari M, et al
    European Respiratory Society statement on frailty in adults with chronic lung disease.
    Eur Respir J. 2023;62:2300442.
    PubMed     Abstract available
    
    
    July 2023
47. NANZER AM, Taylor V, Hearn AP, Kavanagh JE, et al
    The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma.
    Eur Respir J. 2023 Jul 20:2300245. doi: 10.1183/13993003.00245-2023.
    PubMed    
    
    
    
48. CAZZOLA M, Page CP, Matera MG, Rogliani P, et al
    Revisiting Asthma Pharmacotherapy: Where Do We Stand and Where Do We Want to Go?
    Eur Respir J. 2023 Jul 20:2300700. doi: 10.1183/13993003.00700-2023.
    PubMed     Abstract available
    
    
    June 2023
49. ZHU Z, Freishtat RJ, Harmon B, Hahn A, et al
    Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study.
    Eur Respir J. 2023 Jun 15:2300502. doi: 10.1183/13993003.00502-2023.
    PubMed     Abstract available
    
    
    
50. DUIJTS L
    Prematurity-related chronic respiratory disease across the life course.
    Eur Respir J. 2023;61:2300662.
    PubMed    
    
    
    
51. VAN DER VEER T, de Koning Gans JM, Braunstahl GJ, Pieters A, et al
    The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial.
    Eur Respir J. 2023 Jun 1:2300186. doi: 10.1183/13993003.00186-2023.
    PubMed    
    
    
    April 2023
52. EIWEGGER T, Bendien SA
    Defining the questions to be asked in severe asthma trials: data from the COMSA working group.
    Eur Respir J. 2023;61:2202058.
    PubMed    
    
    
    March 2023
53. PULAKKA A, Risnes K, Metsala J, Alenius S, et al
    Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries.
    Eur Respir J. 2023 Mar 29:2201763. doi: 10.1183/13993003.01763-2022.
    PubMed     Abstract available
    
    
    
54. MAHMOUD O, Granell R, Peralta GP, Garcia-Aymerich J, et al
    Early-life and health behaviour influences on lung function in early adulthood.
    Eur Respir J. 2023;61:2001316.
    PubMed     Abstract available
    
    
    
55. CHARRIOT J, Ahmed E, Bourdin A
    Local targeting of TSLP: feat or defeat.
    Eur Respir J. 2023;61:2202389.
    PubMed    
    
    
    
56. SCHNEIDER S, Poglitsch K, Morgenstern C, Quint T, et al
    Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
    Eur Respir J. 2023;61:2201335.
    PubMed     Abstract available
    
    
    
57. BOULET LP, Boulay ME, Cote A, FitzGerald JM, et al
    Airway inflammation and hyperresponsiveness in subjects with respiratory symptoms and normal spirometry.
    Eur Respir J. 2023;61:2201194.
    PubMed     Abstract available
    
    
    
58. NOBLE PB, Donovan GM
    If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease.
    Eur Respir J. 2023;61:2202307.
    PubMed    
    
    
    
59. CORREN J, Brightling CE, Boulet LP, Porsbjerg C, et al
    Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
    Eur Respir J. 2023;61:2202202.
    PubMed    
    
    
    February 2023
60. GAUVREAU GM, Hohlfeld JM, FitzGerald MJ, Boulet LP, et al
    Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
    Eur Respir J. 2023 Feb 23:2201193. doi: 10.1183/13993003.01193-2022.
    PubMed     Abstract available
    
    
    
61. ABDO M, Kirsten AM, von Mutius E, Kopp M, et al
    Minimal Clinically Important Difference for Impulse Oscillometry in Adults with Asthma.
    Eur Respir J. 2023 Feb 9:2201793. doi: 10.1183/13993003.01793-2022.
    PubMed     Abstract available
    
    
    
62. SAVOURE M, Bousquet J, Leynaert B, Renuy A, et al
    Rhinitis phenotypes and multimorbidities in the general population: the CONSTANCES cohort.
    Eur Respir J. 2023;61:2200943.
    PubMed     Abstract available
    
    
    January 2023
63. POLLOCK J, Chalmers JD
    Aspergillus sensitisation: an underappreciated treatable trait in airway disease.
    Eur Respir J. 2023;61:2202042.
    PubMed    
    
    
    
64. FAWCETT KA
    Seeing the trees for the wood: reducing heterogeneity in genomic studies of asthma.
    Eur Respir J. 2023;61:2201931.
    PubMed    
    
    
    December 2022
65. DAVIES D, Hyland ME, Lanario JW, Jones RC, et al
    Moving towards patient-centred outcomes: the Severe Asthma Questionnaire.
    Eur Respir J. 2022 Dec 30:2202305. doi: 10.1183/13993003.02305-2022.
    PubMed    
    
    
    
66. FAROOQI MM, Hambly N, Ryerson CJ, Kolb M, et al
    Reply: risk factors for disease progression in fibrotic hypersensitivity pneumonitis.
    Eur Respir J. 2022 Dec 22:2202261. doi: 10.1183/13993003.02261-2022.
    PubMed    
    
    
    
67. FUJIMOTO H, Yasuma T, D'Alessandro-Gabazza CN, Gabazza EC, et al
    Risk Factors for Disease Progression in Fibrotic Hypersensitivity Pneumonitis.
    Eur Respir J. 2022 Dec 22:2201706. doi: 10.1183/13993003.01706-2022.
    PubMed    
    
    
    
68. RATTU A, Khaleva E, Brightling C, Dahlen SE, et al
    Identifying and appraising outcome measures for severe asthma: a systematic review.
    Eur Respir J. 2022 Dec 22:2201231. doi: 10.1183/13993003.01231-2022.
    PubMed     Abstract available
    
    
    
69. KOCKS J, van der Molen T, Voorham J, Baldi S, et al
    Development of a tool to detect small airways dysfunction in asthma clinical practice.
    Eur Respir J. 2022 Dec 14:2200558. doi: 10.1183/13993003.00558-2022.
    PubMed     Abstract available
    
    
    
70. HAHN DL, Webley W
    U-BIOPRED/BIOAIR proteins: inflammation or infection?
    Eur Respir J. 2022;60:2200571.
    PubMed    
    
    
    
71. SPARREMAN MIKUS M, Kolmert J, Andersson LI, Dahlen SE, et al
    Reply: U-BIOPRED/BIOAIR proteins: inflammation or infection?
    Eur Respir J. 2022;60:2201795.
    PubMed    
    
    
    
72. MENZIES-GOW A, Gurnell M, Heaney LG, Corren J, et al
    Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study.
    Eur Respir J. 2022;60:2103226.
    PubMed     Abstract available
    
    
    November 2022
73. CHERIAN M, Magner KMA, Whitmore GA, Vandemheen KL, et al
    Patient and physician factors associated with symptomatic undiagnosed asthma or COPD.
    Eur Respir J. 2022 Nov 3. pii: 13993003.01721-2022.
    PubMed     Abstract available
    
    
    
74. BUSSE WW
    Improving systemic corticosteroid stewardship in asthma.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
75. PARK JS, Cho YJ, Yun JY, Lee HJ, et al
    Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    
76. ROBERTS G
    Is it time to consider allergen immunotherapy earlier in the management of allergic asthma?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
77. PETSKY H
    Randomised controlled trials utilising F ENO to manage asthma: is it time to acknowledge that "one size does not fit all"?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
78. GODET C, Cadranel J, Frat JP, Ragot S, et al
    Reply to: Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse.
    Eur Respir J. 2022;60:2201678.
    PubMed    
    
    
    
79. LIU Y, Lu HW, Xu JF
    Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse.
    Eur Respir J. 2022;60:2201332.
    PubMed    
    
    
    October 2022
80. KHALEVA E, Rattu A, Brightling C, Bush A, et al
    Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).
    Eur Respir J. 2022 Oct 13. pii: 13993003.00606-2022.
    PubMed     Abstract available
    
    
    
81. POLVERINO F, Marin JM
    The lower respiratory tract: the hot spot for chronic fixed airflow limitation.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
82. HAMBLY N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, et al
    Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    
83. AGARWAL R, Sehgal IS, Muthu V, Dhooria S, et al
    Estimating the minimal important difference in FEV1 for patients with allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    September 2022
84. PERSSON C
    Creola bodies and pathogenesis of childhood asthma.
    Eur Respir J. 2022 Sep 30. pii: 13993003.01204-2022.
    PubMed    
    
    
    
85. LIU J, Bowatte G, Pham J, Perret JL, et al
    Pre-pubertal smoke exposure of fathers and increased risk of offspring asthma: a possible transgenerational effect.
    Eur Respir J. 2022 Sep 14. pii: 13993003.00257-2022.
    PubMed    
    
    
    
86. COLEMAN C, Khaleva E, Rattu A, Frankemolle B, et al
    Narrative Review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma.
    Eur Respir J. 2022 Sep 14. pii: 13993003.00837-2022.
    PubMed     Abstract available
    
    
    
87. SORIANO JB
    Planetary respiratory health for asthma, rhinoconjunctivitis and eczema.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
88. CHAN JSK, Murray RB, Price D
    Oral corticosteroids in asthma and beyond: moving forward.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
89. PAVORD ID
    Case-finding and diagnosis of obstructive airway diseases: the Dragons' Den experience.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
90. PERREM L, Subbarao P
    Moving the dial on identifying endotypes of asthma from early life.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    August 2022
91. CHAN R, Lipworth B
    Interactions between spirometry and oscillometry in patients with moderate to severe asthma.
    Eur Respir J. 2022 Aug 18. pii: 13993003.00543-2022.
    PubMed    
    
    
    
92. LEE S, Prokopenko D, Kelly RS, Lutz S, et al
    Zinc finger protein 33B demonstrates sex-interaction with atopy-related markers in childhood asthma.
    Eur Respir J. 2022 Aug 11. pii: 13993003.00479-2022.
    PubMed     Abstract available
    
    
    
93. TIEW PY, Narayana JK, Li Quek MS, Ang YY, et al
    Sensitisation to recombinant Aspergillus fumigatus allergens and clinical outcomes in COPD.
    Eur Respir J. 2022 Aug 4. pii: 13993003.00507-2022.
    PubMed     Abstract available
    
    
    July 2022
94. PERRET JL, Dharmage SC, Bui DS
    Early life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?
    Eur Respir J. 2022 Jul 26. pii: 13993003.01141-2022.
    PubMed    
    
    
    
95. VAN MEEL ER, Duijts L
    Reply to: "Early-life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?"
    Eur Respir J. 2022 Jul 26. pii: 13993003.01384-2022.
    PubMed    
    
    
    
96. MCLOUGHLIN RF, Clark VL, Urroz PD, Gibson PG, et al
    Increasing physical activity in severe asthma: a systematic review and meta-analysis.
    Eur Respir J. 2022 Jul 26. pii: 13993003.00546-2022.
    PubMed     Abstract available
    
    
    
97. WURZEL D, Licciardi PV
    Targeted strategies are needed to prevent childhood asthma.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
98. VAN HULST G, Jorssen J, Jacobs N, Henket M, et al
    Reply: Ex vivo SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significance.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
99. COUILLARD S
    The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
100. WARK PAB
     We need to understand why viral infections lead to acute asthma.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
101. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
     Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
     Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
     PubMed     Abstract available
     
     
     
102. SALTER B, Zhao N, Son K, Suray Tan N, et al
     Airway autoantibodies are determinants of asthma severity.
     Eur Respir J. 2022 Jul 1. pii: 13993003.00442-2022.
     PubMed     Abstract available
     
     
     
103. REDMOND C, Heaney LG, Chaudhuri R, Jackson DJ, et al
     Benefits of specialist severe asthma management: demographic and geographic disparities.
     Eur Respir J. 2022 Jul 1. pii: 13993003.00660-2022.
     PubMed     Abstract available
     
     
     
104. HOLMES J, McGarvey LP, Birring SS, Fletcher H, et al
     An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma.
     Eur Respir J. 2022 Jul 1. pii: 13993003.03205-2021.
     PubMed     Abstract available
     
     
     June 2022
105. BATEMAN ED, Price DB, Wang HC, Schonffeldt P, et al
     Reply to: Cause or consequence?
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
106. VOLPE FM
     Cause or consequence?
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
107. GODET C, Couturaud F, Marchand-Adam S, Pison C, et al
     Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     May 2022
108. WOEHLK C, Von Bulow A, Ghanizada M, Baastrup Sondergaard M, et al
     Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study.
     Eur Respir J. 2022 May 26. pii: 13993003.00446-2022.
     PubMed     Abstract available
     
     
     
109. SUN Y, Zhang M, Ou Z, Meng Y, et al
     Indoor microbiome, microbial and plant metabolites, chemical compounds and asthma symptoms in junior high school students: a multicentre association study in Malaysia.
     Eur Respir J. 2022 May 26. pii: 13993003.00260-2022.
     PubMed     Abstract available
     
     
     
110. HUMBERT M, Bourdin A, Taille C, Kamar D, et al
     Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics.
     Eur Respir J. 2022 May 26. pii: 13993003.03130-2021.
     PubMed     Abstract available
     
     
     
111. HABENER A, Grychtol R, Gaedcke S, DeLuca D, et al
     IgA(+) memory B cells are significantly increased in patients with asthma and small airways dysfunction.
     Eur Respir J. 2022 May 20. pii: 13993003.02130-2021.
     PubMed     Abstract available
     
     
     
112. KROES JA, Zielhuis SW, De Jong K, Hashimoto S, et al
     Cumulative Corticosteroid Sparing Effect of Anti-Interleukin-5/5Ra In Eosinophilic Asthma.
     Eur Respir J. 2022 May 20. pii: 13993003.02983-2021.
     PubMed     Abstract available
     
     
     
113. GAIETTO K, Han YY, Forno E, Bacharier LB, et al
     Violence-related distress and lung function in two longitudinal studies of youth.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     April 2022
114. RABE KF, Pavord ID, Castro M, Wechsler ME, et al
     Dupilumab efficacy and safety in patients with asthma and blood eosinophils >/=500 cells.microL(-1).
     Eur Respir J. 2022 Apr 29. pii: 13993003.02577-2021.
     PubMed    
     
     
     
115. VAN MEEL ER, Mensink-Bout SM, den Dekker HT, Ahluwalia TS, et al
     Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children.
     Eur Respir J. 2022 Apr 29. pii: 13993003.02395-2021.
     PubMed     Abstract available
     
     
     
116. MENSINK-BOUT SM, van Meel ER, de Jongste JC, Annesi-Maesano I, et al
     Maternal diet in pregnancy and child's respiratory outcomes: an individual participant data meta-analysis of 18 000 children.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
117. SINGH D, Beier J, Astbury C, Belvisi MG, et al
     The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     March 2022
118. THOMAS D, McDonald VM, Pavord ID, Gibson PG, et al
     Asthma remission- what is it and how can it be achieved?
     Eur Respir J. 2022 Mar 31. pii: 13993003.02583-2021.
     PubMed     Abstract available
     
     
     
119. HUYNH C, Whitmore GA, Vandemheen KL, FitzGerald JM, et al
     Derivation and Validation of the UCAP-Q Case-finding Questionnaire to Detect Undiagnosed Asthma and COPD.
     Eur Respir J. 2022 Mar 24. pii: 13993003.03243-2021.
     PubMed     Abstract available
     
     
     
120. HAN YY, Yan Q, Chen W, Celedon JC, et al
     Child maltreatment, anxiety and depression, and asthma among British adults in the UK Biobank.
     Eur Respir J. 2022 Mar 17. pii: 13993003.03160-2021.
     PubMed     Abstract available
     
     
     
121. BAL C, Idzko M, Skrgat S, Koch A, et al
     FeNO is associated with disease burden in the German Asthma Net severe asthma cohort.
     Eur Respir J. 2022 Mar 10. pii: 13993003.01233-2021.
     PubMed    
     
     
     
122. PETNAK T, Thongprayoon C, Baqir M, Ryu JH, et al
     Antigen Identification and Avoidance on Outcomes in Fibrotic Hypersensitivity Pneumonitis.
     Eur Respir J. 2022 Mar 2. pii: 13993003.01336-2021.
     PubMed     Abstract available
     
     
     
123. KLEIN DK, Silberbrandt A, Frossing L, Hvidtfeldt M, et al
     Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma.
     Eur Respir J. 2022 Mar 2. pii: 13993003.02446-2021.
     PubMed     Abstract available
     
     
     
124. VONK JM, Roukema J
     Air pollution susceptibility in children with asthma and obesity: tidal volume as key player?
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
125. THAMRIN C, Robinson PD, Farah CS, King GG, et al
     Technical standards for respiratory oscillometry and bronchodilator response cut-offs.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
126. DAGHER R, Kumar V, Copenhaver AM, Gallagher S, et al
     Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     February 2022
127. ALI GB, Lowe AJ, Perret JL, Walters EH, et al
     Impact of lifetime body mass index trajectories on the incidence and persistence of adult asthma.
     Eur Respir J. 2022 Feb 24. pii: 13993003.02286-2021.
     PubMed     Abstract available
     
     
     
128. MORTIMER K, Reddel HK, Pitrez PM, Bateman ED, et al
     Asthma management in low- and middle-income countries: case for change.
     Eur Respir J. 2022 Feb 24. pii: 13993003.03179-2021.
     PubMed     Abstract available
     
     
     
129. MORTIMER K, Lesosky M, Garcia-Marcos L, Innes Asher M, et al
     The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.
     Eur Respir J. 2022 Feb 24. pii: 13993003.02865-2021.
     PubMed     Abstract available
     
     
     
130. MOSLEMI A, Kontogianni K, Brock J, Wood S, et al
     Differentiating COPD and Asthma using Quantitative CT Imaging and Machine Learning.
     Eur Respir J. 2022 Feb 24. pii: 13993003.03078-2021.
     PubMed     Abstract available
     
     
     
131. MAISON N, Omony J, Illi S, Thiele D, et al
     T-high asthma phenotypes across life span.
     Eur Respir J. 2022 Feb 24. pii: 13993003.02288-2021.
     PubMed     Abstract available
     
     
     
132. TAYTARD J, Koskas M, Beydon N
     Spirometry forced expiratory time is driven by airflow limitation in asthmatic children.
     Eur Respir J. 2022 Feb 10. pii: 13993003.02620-2021.
     PubMed    
     
     
     
133. SKOV IR, Madsen H, Henriksen DP, Andersen JH, et al
     Low dose oral corticosteroids in asthma associates with increased morbidity and mortality.
     Eur Respir J. 2022 Feb 10. pii: 13993003.03054-2021.
     PubMed     Abstract available
     
     
     
134. GARCIA-MARCOS L, Innes Asher M, Pearce N, Ellwood E, et al
     The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study.
     Eur Respir J. 2022 Feb 10. pii: 13993003.02866-2021.
     PubMed     Abstract available
     
     
     
135. MARCON A, Locatelli F, Accordini S
     The coexistence of asthma and COPD: some considerations about prevalence and lung function decline.
     Eur Respir J. 2022 Feb 3. pii: 13993003.00096-2022.
     PubMed    
     
     
     
136. SEYS SF, Long MB
     The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     January 2022
137. GAUVREAU GM, Davis BE, Scadding G, Boulet LP, et al
     Allergen Provocation Tests in Respiratory Research: Building on 50 Years of Experience.
     Eur Respir J. 2022 Jan 27. pii: 13993003.02782-2021.
     PubMed     Abstract available
     
     
     
138. RICCARDI D, Ward JP, Yarova PL, Janssen LJ, et al
     Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?
     Eur Respir J. 2022 Jan 20. pii: 13993003.02103-2021.
     PubMed     Abstract available
     
     
     
139. AL-SHAIKHLY T, Murphy RC, Parker A, Lai Y, et al
     Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma.
     Eur Respir J. 2022 Jan 13. pii: 13993003.01865-2021.
     PubMed     Abstract available
     
     
     
140. RAMIS J, Middlewick R, Pappalardo F, Cairns JT, et al
     Lysyl oxidase-like 2 is increased in asthma and contributes to asthmatic airway remodelling.
     Eur Respir J. 2022 Jan 7. pii: 13993003.04361-2020.
     PubMed     Abstract available
     
     
     
141. PEROTIN JM, Wheway G, Tariq K, Azim A, et al
     Vulnerability to acid reflux of the airway epithelium in severe asthma.
     Eur Respir J. 2022 Jan 7. pii: 13993003.01634-2021.
     PubMed     Abstract available
     
     
     
142. BENSON VS, Hartl S, Barnes N, Galwey N, et al
     Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     December 2021
143. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
     Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
     Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
     PubMed     Abstract available
     
     
     
144. PORSBJERG C, Nieto-Fontarigo JJ, Cerps S, Ramu S, et al
     Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic.
     Eur Respir J. 2021 Dec 16. pii: 13993003.02333-2021.
     PubMed     Abstract available
     
     
     
145. AGARWAL R, Muthu V
     Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.
     Eur Respir J. 2021 Dec 9. pii: 13993003.02989-2021.
     PubMed    
     
     
     
146. HAVETTE A, Regard L, Roche N, Burgel PR, et al
     Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?
     Eur Respir J. 2021 Dec 9. pii: 13993003.02924-2021.
     PubMed    
     
     
     
147. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
     Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
     Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
     PubMed     Abstract available
     
     
     
148. GURDENIZ G, Ernst M, Rago D, Kim M, et al
     Neonatal metabolome of cesarean section and risk of childhood asthma.
     Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
     PubMed     Abstract available
     
     
     
149. RYAN D, Sabroe I
     Identifying and addressing health inequalities in asthma care.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
150. PAPAIOANNOU AI, Photiades A, Gaga M
     Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
151. PARK S, Lee S, Kim Y, Cho S, et al
     Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     November 2021
152. ABDEL-AZIZ MI, Vijverberg SJH, Neerincx AH, Brinkman P, et al
     A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes.
     Eur Respir J. 2021 Nov 25. pii: 13993003.02603-2021.
     PubMed    
     
     
     
153. REINKE SN, Naz S, Chaleckis R, Gallart-Ayala H, et al
     Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study.
     Eur Respir J. 2021 Nov 25. pii: 13993003.01733-2021.
     PubMed     Abstract available
     
     
     
154. MIKUS MS, Kolmert J, Andersson LI, Ostling J, et al
     Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.
     Eur Respir J. 2021 Nov 4. pii: 13993003.00142-2021.
     PubMed     Abstract available
     
     
     
155. OLIVER BG
     Food for thought: why is there more airway smooth muscle in asthma?
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
156. MANNINO DM
     Asthma, COPD and their overlap: coexistence or something more?
     Eur Respir J. 2021;58.
     PubMed    
     
     
     October 2021
157. ELSEY L, Pantin T, Holmes LJ, Tavernier G, et al
     Outcomes over the first two years of treatment with mepolizumab in severe asthma.
     Eur Respir J. 2021 Oct 28. pii: 13993003.01313-2021.
     PubMed     Abstract available
     
     
     
158. PIJNENBURG MW, Frey U, De Jongste JC, Saglani S, et al
     Childhood asthma- pathogenesis and phenotypes.
     Eur Respir J. 2021 Oct 28. pii: 13993003.00731-2021.
     PubMed     Abstract available
     
     
     
159. REDDEL HK, Bacharier LB, Bateman ED, Brightling CE, et al
     Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes.
     Eur Respir J. 2021 Oct 19. pii: 13993003.02730-2021.
     PubMed     Abstract available
     
     
     
160. CHAN R, Misirovs R, Lipworth B
     Repeatability of impulse oscillometry in patients with severe asthma.
     Eur Respir J. 2021 Oct 8. pii: 13993003.01679-2021.
     PubMed    
     
     
     
161. SUN Y, Xia PF, Xie J, Mustieles V, et al
     Association of blood trihalomethane concentrations with asthma in U.S. adolescents: nationally representative cross-sectional study.
     Eur Respir J. 2021 Oct 8. pii: 13993003.01440-2021.
     PubMed     Abstract available
     
     
     
162. PORSBJERG C, Maitland-van der Zee AH, Brusselle G, Canonica GW, et al
     3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     September 2021
163. MIURA S, Iwamoto H, Omori K, Yamaguchi K, et al
     Accelerated decline in lung function in adults with a history of remitted childhood asthma.
     Eur Respir J. 2021 Sep 29. pii: 13993003.00305-2021.
     PubMed     Abstract available
     
     
     
164. PANAGOU P, Tzilas V, Bouros D
     "Dynamic (C dyn) lung compliance in non-smokers with asthma and fixed, non-reversible airflow obstruction" ERJ 2021 58: 2004400.
     Eur Respir J. 2021 Sep 24. pii: 13993003.02361-2021.
     PubMed    
     
     
     
165. BUSBY J, Matthews JG, Chaudhuri R, Pavord ID, et al
     Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.
     Eur Respir J. 2021 Sep 24. pii: 13993003.00768-2021.
     PubMed     Abstract available
     
     
     
166. BATEMAN ED, Price DB, Wang HC, Khattab A, et al
     Short-acting beta2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.
     Eur Respir J. 2021 Sep 24. pii: 13993003.01402-2021.
     PubMed     Abstract available
     
     
     
167. VAN HULST G, Jorssen J, Jacobs N, Henket M, et al
     Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma.
     Eur Respir J. 2021 Sep 2. pii: 13993003.00935-2021.
     PubMed     Abstract available
     
     
     
168. GARCIA-LARSEN V
     Omega-3 polyunsaturated fatty acids and FADS genotype: is personalised prevention of asthma on the horizon?
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
169. RUFFLES T, Lipworth B, Mukhopadhyay S
     Considerations of a real life pragmatic clinical trial in adolescent asthma.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
170. VAN BOVEN JFM, Dierick BJH, Usmani OS
     When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma?
     Eur Respir J. 2021;58.
     PubMed    
     
     
     August 2021
171. ROFFEL MP, Boudewijn IM, van Nijnatten JLL, Faiz A, et al
     Identification of asthma associated microRNAs in bronchial biopsies.
     Eur Respir J. 2021 Aug 26. pii: 13993003.01294-2021.
     PubMed     Abstract available
     
     
     
172. WU M, Xie J, Wang Y, Tian Y, et al
     Greenness and eosinophilic asthma: Findings from the UK Biobank.
     Eur Respir J. 2021 Aug 12. pii: 13993003.01597-2021.
     PubMed    
     
     
     
173. SUNJAYA AP, Allida SM, Di Tanna GL, Jenkins CR, et al
     Asthma and Coronavirus Disease 2019 Risk: a systematic review and meta-analysis.
     Eur Respir J. 2021 Aug 12. pii: 13993003.01209-2021.
     PubMed     Abstract available
     
     
     
174. AFSHAR-MOHAJER N, Wu TD, Shade R, Brigham E, et al
     Obesity, tidal volume, and pulmonary deposition of fine particulate matter in children with asthma.
     Eur Respir J. 2021 Aug 12. pii: 13993003.00209-2021.
     PubMed     Abstract available
     
     
     July 2021
175. BUSSE WW, Paggiaro P, Munoz X, Casale TB, et al
     Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma.
     Eur Respir J. 2021 Jul 29. pii: 13993003.04605-2020.
     PubMed    
     
     
     
176. HAN YY, Forno E, Bacharier LB, Phipatanakul W, et al
     Vitamin D supplementation, lung function, and asthma control in children with asthma and low vitamin D levels.
     Eur Respir J. 2021 Jul 29. pii: 13993003.00989-2021.
     PubMed    
     
     
     
177. CORREN J, Katelaris CH, Castro M, Maspero JF, et al
     Effect of exacerbation history on clinical response to dupilumab in moderate-severe uncontrolled asthma.
     Eur Respir J. 2021 Jul 15. pii: 13993003.04498-2020.
     PubMed     Abstract available
     
     
     June 2021
178. MOORE WC, Kornmann O, Humbert M, Poirier C, et al
     Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study).
     Eur Respir J. 2021 Jun 25. pii: 13993003.00396-2021.
     PubMed     Abstract available
     
     
     
179. KRAFT M, Brusselle G, Mark FitzGerald J, Pavord ID, et al
     Patient characteristics, biomarkers, and exacerbation risk in severe, uncontrolled asthma.
     Eur Respir J. 2021 Jun 10. pii: 13993003.00413-2021.
     PubMed     Abstract available
     
     
     May 2021
180. BENLALA I, Dournes G, Girodet PO, Benkert T, et al
     Evaluation of bronchial wall thickness in asthma using magnetic resonance imaging.
     Eur Respir J. 2021 May 28. pii: 13993003.00329-2021.
     PubMed     Abstract available
     
     
     
181. JENDZJOWSKY N, Laing A, Malig M, Matyas J, et al
     Long-term modulation of airway remodeling in severe asthma following bronchial thermoplasty.
     Eur Respir J. 2021 May 28. pii: 13993003.00622-2021.
     PubMed     Abstract available
     
     
     
182. SVERRILD A, Hansen S, Hvidtfeldt M, Clausson CM, et al
     The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM).
     Eur Respir J. 2021 May 28. pii: 13993003.01296-2021.
     PubMed     Abstract available
     
     
     
183. HAKANSSON KEJ, Backer V, Suppli Ulrik C
     Socioeconomic biases in asthma control and specialist referral of possible severe asthma.
     Eur Respir J. 2021 May 13. pii: 13993003.00741-2021.
     PubMed     Abstract available
     
     
     
184. JOHANSSON H, Wollmer P, Sundstrom J, Janson C, et al
     Bronchodilator response in FOT parameters in middle-aged adults from SCAPIS - normal values and relation to asthma and wheezing.
     Eur Respir J. 2021 May 6. pii: 13993003.00229-2021.
     PubMed    
     
     
     April 2021
185. GAILLARD EA, Kuehni CE, Turner S, Goutaki M, et al
     European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5-16 years.
     Eur Respir J. 2021 Apr 19. pii: 13993003.04173-2020.
     PubMed     Abstract available
     
     
     
186. MARCON A, Locatelli F, Dharmage SC, Svanes C, et al
     The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories.
     Eur Respir J. 2021 Apr 16. pii: 13993003.04656-2020.
     PubMed     Abstract available
     
     
     
187. ESTEVES P, Blanc L, Celle A, Dupin I, et al
     Crucial role of fatty acid oxidation in asthmatic bronchial smooth muscle remodelling.
     Eur Respir J. 2021 Apr 8. pii: 13993003.04252-2020.
     PubMed     Abstract available
     
     
     
188. TALAEI M, Hughes DA, Mahmoud O, Emmett PM, et al
     Dietary intake of vitamin A, lung function, and incident asthma in childhood.
     Eur Respir J. 2021 Apr 1. pii: 13993003.04407-2020.
     PubMed     Abstract available
     
     
     March 2021
189. KNIHTILA HM, Kelly RS, Brustad N, Huang M, et al
     Maternal 17q21 genotype influences prenatal vitamin D effects on offspring asthma/recurrent wheeze.
     Eur Respir J. 2021 Mar 2. pii: 13993003.02012-2020.
     PubMed     Abstract available
     
     
     February 2021
190. REDDEL HK, Vestbo J, Agusti A, Anderson GP, et al
     Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort.
     Eur Respir J. 2021 Feb 25. pii: 13993003.03927-2020.
     PubMed     Abstract available
     
     
     January 2021
191. ROGLIANI P, Ritondo BL, Calzetta L
     Triple therapy in uncontrolled asthma: a network meta-analysis of Phase III studies.
     Eur Respir J. 2021 Jan 28. pii: 13993003.04233-2020.
     PubMed     Abstract available
     
     
     
192. TALAEI M, Sdona E, Calder PC, Jones LR, et al
     Intake of n-3 polyunsaturated fatty acids in childhood, FADS genotype, and incident asthma.
     Eur Respir J. 2021 Jan 28. pii: 13993003.03633-2020.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.